A Breast Cancer Polygenic Risk Score Validation in 15,490 Brazilians 2 using Exome Sequencing

3

⁴ Flávia Eichemberger Rius^{1,2}, Rodrigo Guindalini³, Danilo Viana¹, Júlia Salomão¹,
⁵ Laila Gallo¹, Renata Freitas¹, Cláudia Bertolacini¹, Lucas Taniguti¹, Danilo
⁶ Imparato¹, Flávia Antunes¹, Gabriel Sousa¹, Renan Achjian¹, Eric Fukuyama¹,
⁷ Cleandra Gregório¹, Iuri Ventura¹, Juliana Gomes¹, Nathália Taniguti¹, Simone
⁸ Maistro², José Eduardo Krieger⁴, Yonglan Zheng⁵, Dezheng Huo⁶, Olufunmilayo I.
⁹ Olopade⁵, Maria Aparecida Koike², David Schlesinger¹

10

11 1. Mendelics, São Paulo, Brazil.

12 2. Comprehensive Center for Precision Oncology - C2PO, Centro de Investigação
13 Translacional em Oncologia (CTO), Departamento de Radiologia e Oncologia, Instituto
14 do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP,
15 Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.

16 3. Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil.

17 4. Instituto do Coração, Hospital das Clínicas da Faculdade de Medicina da 18 Universidade de São Paulo - FMUSP, São Paulo, Brazil.

19 5. Medicine and Human Genetics, Center for Clinical Cancer Genetics and Global20 Health, University of Chicago Medical Center, Chicago, USA.

21 6. Department of Public Health Sciences, University of Chicago, Chicago, USA.

23 Abstract

24 Purpose

²⁵ Brazil has a highly admixed population. Polygenic Risk Scores (PRS) have been mostly ²⁶ developed from European population studies and applying them to other populations is ²⁷ challenging. To assess the use of PRS for breast cancer (BC) risk in Brazil, we validated ²⁸ four PRSs developed in the Brazilian population.

29 Patients and Methods

³⁰ We analyzed 6,362 women with a history of breast cancer and 9,128 unphenotyped ³¹ adults as controls in a sample obtained from a clinical laboratory. Genomic variants ³² were imputed from exomes and scores were calculated for all samples.

33 Results

34 After excluding individuals with known pathogenic or likely pathogenic variants in 35 *BRCA1*, *BRCA2*, *PALB2*, *PTEN*, or *TP53*, and first-degree relatives of the probands, 36 5,730 cases and 8,847 controls remained. Four PRS models were compared, and PRS 37 3820 from Mavaddat *et al.* 2019 performed best, with an Odds Ratio (OR) of 1.41 per 38 standard deviation (SD) increase (p-value: < 0.0001) and an OR of 1.94 (p-value: < 39 0.0001) for the individuals in the top risk decile. PRS 3820 also performed well for 40 different ancestry groups: East Asian majority (Group 1), Non-European majority (Group 41 2), and European majority (Group 3), showing significant effect sizes for all groups: 42 (Group 1: OR 1.54, p-value 0.006; Group 2: OR 1.44, p-value: <0.001; Group 3 OR: 43 1.43, p-value: <0.001). PRS 90% compares with monogenic moderate BC risk genes
44 (PRS90 OR: 1.94; CHEK2 OR: 1.89; ATM OR: 1.99).

45 Conclusion

⁴⁶ PRS 3820 can be accurately used in the Brazilian population. This will allow a more⁴⁷ precise BC risk assessment of mutation-negative women in Brazil.

48

49 Introduction

⁵⁰ Breast cancer (BC) is a critical global health concern, representing the most common ⁵¹ cancer diagnosed among women¹. In Brazil, over 70,000 women are diagnosed with BC ⁵² every year, accounting for 30% of all cancers in the female population².

⁵³ Approximately 10% of all BC cases are attributable to germline pathogenic variants in ⁵⁴ susceptibility genes³. Rare variants in high penetrance genes (*BRCA1*, *BRCA2*, *TP53*, ⁵⁵ *PTEN*, and *PALB2*) and in moderate penetrance genes (*CHEK2* and *ATM*) are ⁵⁶ associated with a more than 4-fold and 1.5–4 fold increased risk of BC, respectively^{4, 5}. ⁵⁷ Rare variants in these genes account for approximately 25% of the genetic risk. The ⁵⁸ remaining genetic risk (~75%) is derived from common, low penetrance variants that ⁵⁹ individually confer small risk, but which combined effect can be substantial^{4–6}.

60 Genome-wide association studies (GWASs) have been predominantly carried out in 61 European populations^{7–10}. Evaluation of PRS across different genetic and environmental 62 backgrounds is essential to enable the implementation of genetic risk stratification 63 strategies for individuals from non-European populations¹¹. ⁶⁴ The Brazilian population exhibits a unique, highly admixed, genetic composition. It is ⁶⁵ mostly derived from a combination of Native Americans, Southern Europeans ⁶⁶ (Portuguese, Spanish, and Italian) that immigrated in the period 1500-1900, and ⁶⁷ Sub-Saharan Africans brought through extensive slave trading until the 1800s. More ⁶⁸ recently, from 1822 to the first half of the 1900s, other smaller waves of immigration also ⁶⁹ contributed to Brazil's remarkable diversity, including Japanese, Lebanese, German, ⁷⁰ and Eastern Europeans¹². Three in every four Brazilians have multiple genetic ⁷¹ ancestries^{13,14}. Given Brazil's genetic diversity, any PRS developed in predominantly ⁷² European populations requires validation before it can be used in clinical settings.

73 Several laboratory methods are available for genotyping variants directly or indirectly
74 (imputation), including microarrays, whole exome sequencing (WES), and whole
75 genome sequencing (WGS). WES offers an affordable and scalable alternative to arrays
76 and WGS, while allowing for simultaneous rare and common variant genotyping.
77 In this study, we evaluate four BC PRSs^{7,8,15} developed using WES in 15,490 Brazilians.

78

79 Methods

80 Study population

A total of 15,490 individuals were selected for this study, including 6,362 women with breast cancer history, and 9,128 adult unphenotyped controls. Both clinical and genetic data were collected from a database of a College of American Pathology (CAP)–accredited laboratory (Mendelics, São Paulo, SP, Brazil). All BC and control subjects provided Informed Consentment for use of retrospective anonymized data for ⁸⁶ research purposes. Samples were anonymized before analysis. Clinical records such as
⁸⁷ BC histological type and age of diagnosis were obtained from genetic test requisitions.
⁸⁸ The study was IRB-approved (CAAE: 70112423.3.0000.0068).

89

90 Relatedness calculation and data filtering

91 Relatedness of individuals was obtained from the exomes using somalier software¹⁶, 92 following the standard protocol required VCF file for а 93 (https://github.com/brentp/somalier#readme). Concerning related individuals removal, if 94 two individuals had a first-degree relationship, one of them was randomly selected to be 95 included in the dataset. However, if individuals had two or more first-degree 96 relationships, all related individuals were excluded from the dataset. This process 97 resulted in a total of 211 removals. Furthermore, 73 individuals were removed from the 98 sample due to unavailability of files necessary for genome imputation.

⁹⁹ PRS analyses were performed after filtering out cases and controls with pathogenic or ¹⁰⁰ likely-pathogenic (P/LP) variants in BC genes *BRCA1*, *BRCA2*, *TP53*, *PALB2*, and *PTEN*.

102 Exome sequencing and imputation

103 Exome sequencing data were generated from buccal swab or venous blood samples 104 with standard protocol for Illumina Flex Exome Prep, using a custom probe set from 105 Twist Biosciences. Sequencing was conducted in Illumina sequencers and the 106 bioinformatics pipeline for data analysis followed Broad Institute's GATK best practices 107 (https://gatk.broadinstitute.org/hc/en-us/sections/360007226651-Best-Practices-Workflo108 ws), with alignment to GRCh38.

109 Imputation of exomes was based on a panel of 2,504 individuals of all ancestries from 110 the 1000 (1KGP)¹⁷ Genomes Project on GRCh38 (2017 release) 111 (https://www.internationalgenome.org/data-portal/data-collection/grch38). regions All 112 captured from the exome sequencing comprehending at least 1x coverage, as well as 113 off-target regions, were considered for the imputation, performed using Glimpse (v1.1.0) 114 software¹⁸.

115

116 Polygenic Risk Score calculation

¹¹⁷ Four BC PRSs with publicly available summary statistics, from three different studies, ¹¹⁸ were evaluated in this work: Khera *et al.* 2018⁷, with 5,218 variants; Mavaddat *et al.* ¹¹⁹ 2019⁸ PRSs (with 313 and 3,820 variants); and UK Biobank¹⁵ (UKBB) PRS obtained ¹²⁰ from a variant thresholding (p-value < 10e-5) on summary statistics for phenotype code ¹²¹ 20001_1002, with 7,538 variants.

122 The PRS variants were selected based on exome bed kit distance and minor allele 123 frequency (MAF). Additionally, the PRS from Mavaddat study, originally with 3,820 124 variants, had a pathogenic variant of moderate-penetrance in *CHEK2* gene (*CHEK2* 125 p.lle157Thr - Clinvar: RCV000144596) that was removed to avoid conflation with 126 monogenic risk.

127 PRS calculation was performed using a software developed by Mendelics, evaluating 128 the weighted sum of beta values, in which weights are based on the number of the individual's alleles containing the variant of the PRS file. The sum is normalized by allbeta positive and negative values so the final value can be between zero and one.

131

132 Genetic Principal Component Analyses (PCA) Assessment

133 PCA was calculated for exomes from a projection in 1KGP¹⁷ and Human Genome 134 Diversity Project (HGDP)¹⁹ samples. Only variants with MAF > 1% and that could have 135 been directly genotyped using WES were included for the PCA analysis in 1KGP and 136 HGDP samples using plink2²⁰. Exomes were converted to plink bfile format (bed, bim, 137 and fam files) and had duplicated variants removed. PCA projection for 10 PCs was 138 calculated using plink2 –score method, with allele frequencies from the breast cancer 139 case-control sample.

140

141 Ancestry evaluation

Admixture²¹ was used to extract continental ancestries from all non-related and data completed exomes. The analysis was supervised by the 1KGP samples, after removal Add of South Asian, Oceania, and admixed Americans from the GRCh38 1KGP release of South Asian and Oceania ancestries were removed because they are not a Add significant part of Brazilian ancestral composition. Latin American admixed populations (Colombian, Peruvian, Puerto Rican, and Mexican) were removed to avoid confounding with the native americans belonging to the same population label. Continents evaluated were: Africa - AFR, America - AMR, East Asia - EAS, and Europe - EUR. Ancestry 150 results were further used for splitting individuals into groups according to their ancestry151 composition, to further analyze the effect size of PRS on each group.

152

153 Paired imputed and sequenced genomes analysis

Exome-imputed variants and directly sequenced variants from WGS were compared 155 using 1001 samples from an independent Brazilian population dataset 156 (http://elsabrasil.org/) that had both WES and WGS available. The WES were 157 sequenced and imputed also using the same method previously described. BC 158 PRS-3820 from Mavaddat *et al.* study was calculated for both imputed and sequenced 159 genomes, and their Spearman correlation was calculated using R software base 160 function *cor.test*.

161

162 Statistical analyses

163 PRS values were standardized according to the control values prior to all statistical 164 analyses. PCs were Z-scored prior to analyses. To assess the effect size of PRS on 165 breast cancer status (0 = control, 1 = case) corrected for PCs, Odds Ratio (OR) per 166 standard deviation of PRS was calculated by performing a logistic regression of BC 167 status with PRS and PCs 1 to 10 as predictors. AUC for the full dataset evaluation was 168 obtained using the yardstick R package (<u>yardstick.tidymodels.org/</u>) roc_auc function, in 169 the testing data split (25%). In order to find segmentation effect-sizes, individuals were 170 classified into deciles or percentiles following the left-open and right-closed intervals. 171 OR for deciles was calculated by first selecting only the decile analyzed and the interval 172 from 40-60% individuals as the control section, and binarizing it (0 = belongs to the 173 control interval 40-60%, 1 = belongs to the decile analyzed, for example, 10%); and 174 performing a logistic regression analysis on the binarized decile information with 175 correction for PCs 1 to 10. A similar approach was conducted for calculating the OR on 176 percentiles for comparison with Mavaddat's⁸ PRS validation. For each ancestry 177 proportion group, AUC was estimated using 10-fold cross-validation with the R package 178 *caret*²². All PRS 95% confidence intervals (CI) were obtained from the logistic 179 regression output from the R function *glm* (stats package²³). OR and CI for genes 180 *BRCA1*, *BRCA2*, *PALB2*, *TP53*, *ATM* and *CHEK2* were obtained using *epitools* R 181 package²⁴. All statistical tests performed were two-tailed.

182

183 Results

184 Case-control sample selection and characteristics

After removal of 211 subjects with a first-degree relationship and 73 with missing files necessary for imputation, a total of 15,206 subjects remained (**Supplementary Table 1**87 **1**). Four percent of all cases and controls were removed from the analysis due to their necessary for pathogenic or likely-pathogenic (P/LP) variants in high penetrance genes persence of pathogenic or likely-pathogenic (P/LP) variants in high penetrance genes necessary with OR > 5 for breast cancer: *BRCA1*, *BRCA2*, *TP53*, *PALB2*, and *PTEN* (n = 629). Therefore, the sample used for PRS evaluation consisted of 5,730 women with a BC necessary and 8,847 unphenotyped controls, both with known sex and age (**Table 1**).

192

193 Table 1. Demographics of cases and controls in BC dataset used for PRS evaluation

		Case	Control	Total	p value
	Total	5,730	8,847	14,577	-
Sex	F	4,225	5,730	9,955	-
	м	-	4,662	4,662	-
Age	Total	49.5 (11.7)	41.6 (13.3)	44.8 (13.3)	0.000
	F	49.5 (11.7)	42 (13.7)	46.4 (13.1)	0.000
	М	-	41.3 (12.9)	41.3 (12.9)	-

194 p-values obtained from two-tailed t-tests.

195

196 Ancestry composition of our sample was obtained using ADMIXTURE analysis²¹, 197 supervised by EUR, EAS, AFR and non-admixed AMR populations of 1KGP and HGDP. 198 The results show that the majority of individuals have EUR as their greatest ancestry 199 proportion (median 84%, SD 18%). Besides that, a significant portion of AFR (median 200 6%, std. dev. 12%) and AMR (median 8%, SD 7%) ancestries are present, 201 complemented with a variety of EUR proportions. A small quota of EAS is also observed 202 (median < 1%, SD 12%), composed by 214 individuals with over 70% of this ancestry.



203

Figure 1. Ancestry composition of our Brazilian cohort. Estimated ancestries are shown as proportions per individual. Each thin bar represents one individual and their ancestry proportion. Europe (EUR) in purple, Africa (AFR) in blue, East Asia (EAS) in green and America (AMR) in yellow.

208

209 Effect sizes of four different PRSs in the Brazilian population

Four PRS files from three studies were selected for initial effect size investigation in our Construction (**Supplementary Table 2**). All four PRS files had their variants further filtered to address only variants covered by the imputation of our exomes.

213

PCA was performed on the exomes to capture the population genetic structure. PRSs were calculated for the imputed genomes (details described in the **Methods**) and standardized by z-score to improve interpretability. To avoid confounding from P/LP variants on PRS effect, we have evaluated only individuals without those rare variants f(n = 14,577). Effects were corrected for the ten first PCs, and results are all reported in **Supplementary Table 3**.

220

221 Both PRS_{Broad} and PRS₃₈₂₀ performed well, with very significant effect sizes (both 222 p-values < 0.0001) following the direction of risk rise as the PRS increases (OR_{Broad}: 223 1.52; OR₃₈₂₀: 1.41). PRS₃₁₃ and PRS_{UKBB} have not reached significance level for their OR 224 results (p-value₃₁₃: 0.315 and p-value_{UKBB}: 0.985). Goodness of fit of the model is also 225 greater for PRS₃₈₂₀ (Nagelkerke pseudo-R²: 0.061) and PRS_{Broad} (Nagelkerke 226 pseudo-R²: 0.051). Note that pseudo-R² values should not be interpreted as a linear 227 regression R² value, but as a metric of improvement from null model to fitted model, 228 which has its value mainly by being compared between different PRS models in which a 229 greater pseudo-R² indicates a better goodness of fit to the data.

230

Since PRS_{Broad} and PRS_{3820} showed significant results per standard deviation, they were used to split the data into deciles to evaluate BC risk conferred by PRS in each strata. These analyses were also corrected for the first ten PCs. Interestingly, shorter confidence intervals and a better "staircase" shape can be seen for PRS_{3820} plot in comparison to PRS_{Broad} (**Figure 2**). Moreover, especially the top 10% (90-100% interval) present a much greater effect for PRS_{3820} (OR_{90-100} : 1.94; CI: 1.71 - 2.20) compared to 237 PRS_{Broad} (OR₉₀₋₁₀₀: 1.77; CI: 1.51 - 2.10) (**Supplementary Table 4**), indicating a better 238 performance of the former in identifying women with increased risk of BC. Therefore we 239 decided to focus our next analyses on PRS₃₈₂₀, which was the best PRS to identify BC 240 risk in our Brazilian population.





242

243 Figure 2. Effect sizes by decile of PRS₃₈₂₀ and PRS_{Broad}. Odds Ratios (OR) and 244 Confidence Intervals (CI) for PRS₃₈₂₀ (red) and PRS_{Broad} (blue). ORs for both PRS 245 deciles were corrected for the first ten PCs.

246

247 PRS₃₈₂₀ performance compared with the original study

248 As seen in the previous results, the PRS_{3820} showed a positive association with 249 increased risk of BC (OR per standard deviation: 1.41; CI: 1.36 - 1.47) after correction for the first 10 principal components (PCs). This association was slightly lower when compared to the original study test set, composed of only Europeans (OR: 1.66; CI: 252 1.61 - 1.70). Besides that, performance of our model with PRS₃₈₂₀ in identifying BC cases was very similar to the original study (AUC_{Brazilians}: 0.610 vs. AUC_{Europeans}: 0.636). 254 After calculating OR per percentiles, we observed that the PRS₃₈₂₀ exhibited an 255 expressive risk increase for our admixed population, although the increase was smaller 256 than the original study, which applied the PRS₃₈₂₀ to a population with the same 257 ancestry it was originated from (OR_{Brazilians} >99: 2.72; OR_{Europeans} >99: 3.95).



Figure 3. Comparison of PRS₃₈₂₀ performance for Europeans and Brazilians. The
plot shows the PRS₃₈₂₀ adapted in this study (orange), with 2,892 variants, compared
with the original from Mavaddat *et al.* study (blue), with 3,820 variants.

263

The lower interval, comprehending the lowest 1% of PRS values, showed a smaller decrease in BC risk compared to the original study. This result is probably related to the and sample size of this section, with only 31 cases and 88 controls available to calculate OR. In addition, the 95th to 99th percentile interval exhibited marginal growth in odds ratio (OR) when contrasted with the interval immediately below (OR 90th-95th: 1.75, OR 95th-99th: 1.83). Besides that, both effect sizes show an expressive increase in BC risk due to PRS results. This might be partly due to the cohort sample size. Our study evaluated a total of 14,577 individuals, while Mavaddat's evaluated twice this number in their test dataset composed of joined cohorts (n = 29,751).

273

274 PRS evaluation by ancestry composition

275 Since our sample contains a great majority of EUR ancestry proportion, we decided to 276 evaluate the PRS effect size in different ancestry compositions. We have created three 277 groups: EAS majority (> 50% EAS, n = 217), 0 - 50% EUR (n = 763) and 51 - 100% 278 EUR (n = 13,597). All three bins had statistically significant (p < 0.001) ORs above 1.40 279 (1.54, 1.44 and 1.43, respectively) per PRS standard deviation, showing a positive 280 association of the PRS value with increased BC risk. The EAS majority group shows a 281 wider confidence interval due to the small sample size (cases = 64, controls = 153). 282 Besides that, the lower tail of the 95% confidence interval has an OR of 1.14 283 (**Supplementary Table 5**), which means at least 14% risk rise for each unit of 284 standardized PRS increase.



285

Individual

Β.



286

287

Figure 4. Breast cancer Odds Ratio by ancestry proportion. The cohort was split into three groups based on main ancestry: EAS majority (>50% EAS), 0 - 50% EUR and EVR (A) Ancestry composition of each group, with colors representing continental ancestries for each subject. (B) Breast cancer ORs by PRS₃₈₂₀ standard eviation for the three groups. p-values displayed were corrected for multiple-hypothesis testing using Bonferroni method.

295 Comparison of PRS derived from genomes imputed from exomes with WGS

²⁹⁶ A correlation of 0.76 (p value < 2.2e-16) was obtained between BC PRS₃₈₂₀ values
²⁹⁷ calculated from imputed genomes and WGS, showing a consistent concordance
²⁹⁸ between both methods (Supplementary Figure 1A).

299

When we compared imputed (exome) and sequenced genomes (WGS), most of the values were concordant (decile 1: 56%; decile 10: 60%) **Complementary Figure 1B**). Furthermore, most of the proportion which is not in the same decile is in the surrounding deciles, which indicates a low deviation from the purpose of predicting risk.

305

306 Comparison of PRS and breast cancer genes effect size

For the purpose of understanding how the PRS₃₈₂₀ effect size compare to known high
and moderate risk genes for BC, we have compared OR of the top PRS₃₈₂₀ decile
(PRS90) with all pathogenic variants located in *TP53*, *BRCA1*, *BRCA2*, *PALB2*, *ATM*and *CHEK2* genes (Figure 5) in this cohort of individuals.



Figure 5. Effect sizes of 90th percentile of PRS and BC genes in BC risk. Effect (OR and CI) were obtained according to the presence of pathogenic variants in the genes *TP53*, *BRCA1*, *BRCA2*, *PALB2*, *ATM* and *CHEK2*, or belonging to the 90th to 100th percentiles of PRS₃₈₂₀.

316

311

As expected, *TP53*, *BRCA1* and *BRCA2* present the most extreme BC risks (OR: 14.05, 318 CI: 4.1-95.05; OR: 13.43, CI: 9.25-20.32; and OR: 8.77, CI: 6.15-12.93, respectively). 319 PRS90 risk (OR: 1.94, CI:1.71-2.2) can be compared with moderate risk BC genes *ATM* 320 (OR: 1.99, CI: 1.42-2.78) and *CHEK2* (OR: 1.89, CI: 1.35-2.66). This result indicates 321 how an increased risk for BC due to PRS90 could be interpreted in the clinical context, 322 potentially following the same care protocols as for a moderate risk monogenic variant 323 for BC.

325 Discussion

³²⁶ In the present study we have validated a breast cancer PRS developed from Europeans ³²⁷ in the highly admixed Brazilian population. The PRS adapted from Mavaddat *et al.* study ³²⁸ with 2,892 variants⁸ showed a statistically significant risk prediction value (OR: 1.41 per ³²⁹ SD). Furthermore, individuals classified in the top decile had an expressive effect size ³³⁰ (OR: 1.94; CI: 1.71 - 2.20) of almost one-fold increased risk of BC compared to the ³³¹ middle percentiles (40-60%). This PRS highest decile risk is comparable with the ³³² previously reported risks for moderate-penetrance monogenic variants in *ATM*, *NF1*, ³³³ and *CHEK2* genes (1.82, 1.93, and 2.47 OR, respectively)²⁵, and also with risks in *ATM* ³³⁴ and *CHEK2* calculated in our sample (1.99 and 1.89 OR, respectively).

335

This study is based on a previous study from Mavaddat et al. 2019, which developed ar and validated a PRS with 3,820 variants evaluating aggressive BC risk (metastatic BC). Bro all BC subtypes (ER+ and ER-) they found an OR of 1.71 per SD (CI: 1.64 1.79) in the validation set (n = 29,751; cases = 11,428), and OR 1.66 per SD (CI: 1.61 - 1.70) in the prospective set (n = 190,040; cases = 3,215). These values are even greater to the widely used 313 PRS (OR: 1.65 per SD; CI: 1.59 - 1.72 in validation set). However, they included a *CHEK2* gene pathogenic variant in the PRS and worked with only aggressive BC, which may have led to overestimating their OR values. A study and the prospective set and colleagues has evaluated another modification of the same PRS with save from Liu and colleagues has evaluated another modification of the same PRS with at 53,820 variants developed from Mavaddat *et al.* for African, Latin, and European ³⁴⁶ populations²⁶. According to the study, the effect size of this PRS to a BC risk in an ³⁴⁷ European sample (n = 33,594) was 1.40 per standard deviation, a result very similar to ³⁴⁸ ours for a Brazilian sample (OR 1.41 per SD; n = 14,477). They deliberately have ³⁴⁹ included women with *in situ* ductal BC as well as women with metastatic BC, what they ³⁵⁰ claim to be a reason for OR decline compared to the original study, which included only ³⁵¹ metastatic BC women both in their discovery and validation sets. Our study, however, ³⁵² does not distinguish BC types, therefore we hypothesize that both metastatic and *in situ* ³⁵³ BC are included, which may be a factor, together with genetic population structure, that ³⁵⁴ decreased the OR compared to the original study.

355

standard deviation were obtained for standard deviation were obtained for distinct ancestry compositions within our sample. Due to the high proportion of EUR standard deviation were obtained for uncestry compositions. Despite the small sample size (n = 217) of the EAS majority ancestry compositions. Despite the small sample size (n = 217) of the EAS majority group (**Supplementary Table 5**), there was a statistical significance (adjusted p-value: and 0.006) for the effect size in this group, which had similar magnitude (OR: 1.54, CI: and 1.40-2.12) of the full sample (OR: 1.41, CI: 1.36-1.47, p-value: < 0.0001). Also, PRS₃₈₂₀ and significant and expressive effect sizes on BC risk for both EUR proportion groups and (0-50% EUR OR: 1.44, CI: 1.23-1.69; 51-100% EUR OR: 1.43, CI: 1.38-1.49). These ass results evidence that, for individuals with a more prominent East Asian ancestry, for and admixed individuals, and for predominantly Europeans, PRS₃₈₂₀ is still effective in stratifying BC risk.

368

369 All of our PRS values were calculated according to a new methodology: the imputation 370 of genomes from exomes. This approach has demonstrated to be very successful for 371 PRS calculation and assessment of BC risk in our study, and could be very interesting 372 for laboratories that already perform exome sequencing as a cost-effective methodology 373 to identify P/LP variants for BC. A variety of studies have compared low-pass genome 374 sequencing with arrays for different applications, such as pharmacogenetics, GWAS, 375 CNV detection, and PRS calculation^{27,28,29}. The study of Li et al.²⁸ reported improved 376 accuracy for polygenic risk prediction of imputed low-pass genome compared to array 377 imputation for both coronary artery disease and BC. Despite the slight difference we 378 found between PRS values calculated from sequenced genomes and imputed genomes 379 from exomes (Spearman correlation: 0.76), decile classification showed satisfactory 380 concordance between both methods for the majority of results in the extreme deciles (1 381 and 10th), which are the most important to define decreased or increased risk. 382 Unfortunately, it was not possible to assess the predictive power of PRS values 383 calculated from genomes of BC patients due to unavailability of paired exome and 384 genome data.

385

Among familial BC cases, approximately 25% have a P/LP germline variant reported³⁰. In the Brazilian population, a robust study with 1,663 breast cancer patients detected 20.1% of P/LP germline variants using multigene panel testing^{4,6}. A 2017 study reported 289 that 18% of the hereditary BC can be explained by a polygenic effect of variants 290 discovered in a GWAS³¹. Therefore, employing this PRS in the clinical practice might 291 bring an elucidation to BC Brazilian families without high or moderate-effect germline ³⁹² variants detected. Moreover, women without prior knowledge of their familial BC ³⁹³ condition, or even those with a high PRS risk by chance, will have the possibility to be ³⁹⁴ informed of their results and share them with their physicians to adopt preventive ³⁹⁵ actions accordingly to their risk strata, such as intensifying surveillance adding breast ³⁹⁶ magnetic resonance imaging to mammography screening³².

397

In conclusion, our work was able to validate a PRS developed in Europeans in the Brazilian population, using imputed genomes from exomes. The top decile of this PRS with Presents a risk comparable to moderate-risk monogenic variants for BC. Future studies will be required to evaluate the combination of PRS with P/LP variants and clinical factors in order to deliver more informative results to patients, thus physicians can are recommend prevention strategies based on their combined polygenic and monogenic BC risk.

405

406 Ethics Statement

407 This work was approved by the Ethics Committee Comissão para análise de projeto de 408 pesquisa of Hospital das Clínicas da FMUSP - CAPPesq under the CAAE number 409 70112423.3.0000.0068.

411 Acknowledgements

⁴¹² We thank all individuals once sequenced in Mendelics laboratory who have consented ⁴¹³ to participate in this research. We also thank all UKBB participants for their contribution ⁴¹⁴ to the PRS hereby analyzed, and all authors from previous studies on BC PRSs in ⁴¹⁵ which we based our validation (Khera *et al.* 2018 and Mavaddat *et al.* 2019). Maria ⁴¹⁶ Aparecida Azevedo Koike Folgueira received research support from Conselho Nacional ⁴¹⁷ de Desenvolvimento Científico e Tecnológico, Brazil (CNPq-308052/2022-6).

418

419 Data Availability

420 All variants and betas which compose the four evaluated PRSs are available as 421 Supplementary Information. Individual cases and controls data are not publicly available 422 due to the confidentiality consentment agreement signed by all included in the study. 423

424 Competing Interests

Flávia Eichemberger Rius, Danilo Viana, Júlia Salomão, Laila Gallo, Renata Freitas,
Cláudia Bertolacini, Lucas Taniguti, Danilo Imparato, Flávia Antunes, Gabriel Sousa,
Renan Achjian, Eric Fukuyama, Cleandra Gregório, Iuri Ventura, Juliana Gomes,
Nathália Taniguti, and David Schlesinger are currently employed by Mendelics, or were
employed at the time of the study.

410

⁴³⁰ Rodrigo Guindalini acted as a consultant for AstraZeneca, Janssen Oncology,
⁴³¹ Roche/Genentech and Igenomix; received speaker honoraria from AstraZeneca, Bristol
⁴³² Myers Squibb, GlaxoSmithKline, Merck Sharpe & Dohme Brasil, Novartis, and Roche
⁴³³ outside the submitted work; and has equity in Mendelics Análise Genômica.

434 Olufunmilayo I. Olopade is co-founder at CancerIQ; serves as scientific advisor at 435 Tempus; and has received research funding from Color Genomics and 436 Roche/Genentech.

437 José Eduardo Krieger, Yonglan Zheng, Dezheng Huo, Simone Maistro and Maria
438 Aparecida Koike declare no competing interests.

439 Author Contributions

<u>440 Generated Main Data</u>: Flávia Eichemberger Rius, Danilo Viana, Júlia Salomão, Laila
<u>441 Gallo, Renata Freitas, Cláudia Bertolacini, Lucas Taniguti, Danilo Imparato, Flávia</u>
<u>442 Antunes, Gabriel Sousa, Renan Achjian, Eric Fukuyama, David Schlesinger.</u>

<u>Analyzed Data</u>: Flávia Eichemberger Rius, Rodrigo Guindalini, Danilo Viana, Lucas
Taniguti, Danilo Imparato, Flávia Antunes, Gabriel Sousa, Renan Achjian, Eric
Fukuyama, Yonglan Zheng, Dezheng Huo, Olufunmilayo I. Olopade, Maria Aparecida
Koike, David Schlesinger.

<u>447 Other Contributions</u>: Cleandra Gregório, Iuri Ventura, Juliana Gomes, Nathália Taniguti,
<u>448 Simone Maistro, José Eduardo Krieger.</u>

449

450 References

451 1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence

- and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **71**,
 209–249 (2021).
- 454 2. Instituto Nacional de Câncer. *Estimativa 2023 : incidência de câncer no Brasil.*455 (Ministério da Saúde, 2023).
- 456 3. Nielsen, F. C., van Overeem Hansen, T. & Sørensen, C. S. Hereditary breast and
 457 ovarian cancer: new genes in confined pathways. *Nat. Rev. Cancer* 16, 599–612
 458 (2016).
- 459 4. Guindalini, R. S. C. *et al.* Detection of germline variants in Brazilian breast cancer
- patients using multigene panel testing. *Sci. Rep.* **12**, 4190 (2022).
- 461 5. Shiovitz, S. & Korde, L. A. Genetics of breast cancer: a topic in evolution. Ann.
- 462 Oncol. **26**, 1291–1299 (2015).
- 463 6. Melchor, L. & Benítez, J. The complex genetic landscape of familial breast cancer.
- 464 Hum. Genet. **132**, 845–863 (2013).
- 465 7. Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify
- individuals with risk equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224
 (2018).
- 468 8. Mavaddat, N. *et al.* Polygenic risk scores for prediction of breast cancer and breast
 469 cancer subtypes. *Am. J. Hum. Genet.* **104**, 21–34 (2019).
- 470 9. Zhang, H. et al. Genome-wide association study identifies 32 novel breast cancer
- susceptibility loci from overall and subtype-specific analyses. *Nat. Genet.* **52**,
- 472 572–581 (2020).
- 473 10. Morra, A. et al. Association of germline genetic variants with breast cancer-specific
- survival in patient subgroups defined by clinic-pathological variables related to

- tumor biology and type of systemic treatment. *Breast Cancer Res.* **23**, 86 (2021).
- 476 11. Mars, N. et al. Genome-wide risk prediction of common diseases across ancestries
- in one million people. *Cell Genomics* **2**, None (2022).
- 478 12. Salzano, Freire-Maia, F. M. N. As origens. in Populações Brasileiras: Aspectos
- 479 Demográficos, Genéticos e Antropológicos (1967).
- 480 13. Souza, A. M. de, Resende, S. S., Sousa, T. N. de & Brito, C. F. A. de. A systematic
 scoping review of the genetic ancestry of the Brazilian population. *Genet. Mol. Biol.*482 42, 495–508 (2019).
- 483 14. Naslavsky, M. S. et al. Whole-genome sequencing of 1,171 elderly admixed
- individuals from São Paulo, Brazil. *Nat. Commun.* **13**, 1004 (2022).
- 485 15. Sudlow, C. et al. UK Biobank: an open access resource for identifying the causes of
- a wide range of complex diseases of middle and old age. *PLoS Med.* 12, e1001779
 (2015).
- 488 16. Pedersen, B. S. et al. Somalier: rapid relatedness estimation for cancer and
- germline studies using efficient genome sketches. *Genome Med.* **12**, 62 (2020).
- 490 17. 1000 Genomes Project Consortium et al. A global reference for human genetic
- variation. *Nature* **526**, 68–74 (2015).
- 492 18. Rubinacci, S., Ribeiro, D. M., Hofmeister, R. J. & Delaneau, O. Efficient phasing
- and imputation of low-coverage sequencing data using large reference panels. *Nat.*
- 494 *Genet.* **53**, 120–126 (2021).
- 495 19. Bergström, A. *et al.* Insights into human genetic variation and population history
 496 from 929 diverse genomes. *Science* **367**, (2020).
- 497 20. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and

- richer datasets. *Gigascience* **4**, 7 (2015).
- 499 21. Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of
- ancestry in unrelated individuals. *Genome Res.* **19**, 1655–1664 (2009).
- 501 22. Kuhn, M. Building Predictive Models in *R* Using the caret Package. *J. Stat. Softw.*
- **502 28**, (2008).
- 503 23. R Foundation for Statistical Computing. R: A Language and Environment for
- 504 Statistical Computing. (https://www.R-project.org/, 2023).
- 505 24. Aragon, T. J., Fay, M. P., Wollschlaeger, D. & Omidpanah, A. epitools:
- 506 Epidemiology Tools. Tools for training and practicing epidemiologists including
- 507 methods for two-way and multi-way contingency tables. (CRAN, 2020).
- 508 25. Hu, C. et al. A Population-Based Study of Genes Previously Implicated in Breast
- 509 Cancer. N. Engl. J. Med. **384**, 440–451 (2021).
- 510 26. Liu, C. et al. Generalizability of polygenic risk scores for breast cancer among
- women with european, african, and latinx ancestry. *JAMA Netw. Open* **4**, e2119084
- **512** (2021).
- 513 27. Wasik, K. *et al.* Comparing low-pass sequencing and genotyping for trait mapping
 514 in pharmacogenetics. *BMC Genomics* 22, 197 (2021).
- 515 28. Li, J. H., Mazur, C. A., Berisa, T. & Pickrell, J. K. Low-pass sequencing increases
- the power of GWAS and decreases measurement error of polygenic risk scores
- compared to genotyping arrays. *Genome Res.* **31**, 529–537 (2021).
- 518 29. Chaubey, A. et al. Low-Pass Genome Sequencing: Validation and Diagnostic Utility
- from 409 Clinical Cases of Low-Pass Genome Sequencing for the Detection of
- 520 Copy Number Variants to Replace Constitutional Microarray. J. Mol. Diagn. 22,

- **521** 823–840 (2020).
- 522 30. Bahcall, O. Common variation and heritability estimates for breast, ovarian and
- prostate cancers. *Nat. Genet.* (2019) doi:10.1038/ngicogs.1.
- 524 31. Michailidou, K. et al. Association analysis identifies 65 new breast cancer risk loci.
- 525 Nature **551**, 92–94 (2017).
- 526 32. Monticciolo, D. L., Newell, M. S., Moy, L., Lee, C. S. & Destounis, S. V. Breast
- 527 Cancer Screening for Women at Higher-Than-Average Risk: Updated
- 528 Recommendations From the ACR. J. Am. Coll. Radiol. (2023)
- ⁵²⁹ doi:10.1016/j.jacr.2023.04.002.